GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Drug: GW786034, oralDrug: GW786034, radiolabeled oralDrug: GW786034, IV
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT00478725
- Locations
- 🇺🇸
GSK Investigational Site, Nashville, Tennessee, United States
Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
- Conditions
- Neoplasms, BreastMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 51
- Registration Number
- NCT00477464
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above
- Conditions
- Influenza
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 120
- Registration Number
- NCT00476307
- Locations
- 🇩🇪
GSK Investigational Site, Freital, Sachsen, Germany
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: GSK573719
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00475436
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.
- Conditions
- DementiaMild Cognitive Impairment
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5
- Registration Number
- NCT00474513
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.
- Conditions
- Healthy SubjectsDyslipidaemiasDyslipidaemia
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 66
- Registration Number
- NCT00474864
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal vaccine GSK134612 (Nimenrix)Biological: Priorix-TetraBiological: Meningitec
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1000
- Registration Number
- NCT00474266
- Locations
- 🇫🇮
GSK Investigational Site, Vantaa, Finland
Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib
- Conditions
- Hepatitis BWhole Cell PertussisDiphtheriaTetanusHaemophilus Influenzae Type b
- Interventions
- Biological: Zilbrix-HibBiological: Tritanrix™-HepB/ Hiberix™
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00473668
- Locations
- 🇮🇳
GSK Investigational Site, Varanasi, India
Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors
- Conditions
- Obsessive-Compulsive Disorder
- First Posted Date
- 2007-05-10
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT00471588
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.
- Conditions
- Osteoporosis
- Interventions
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 564
- Registration Number
- NCT00471237
- Locations
- 🇪🇸
GSK Investigational Site, Santiago de Compostela, Spain